Transplant Center

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Pilot Study Examining Thiamine Deficiency in Patients Admitted to the Hospital for Liver Transplantation

   Jacksonville, Fla.

   The purpose of this study is to report the proportion of thiamine deficiency (as defined by the Mayo Clinic Laboratory reference range) in liver transplant patients.

2. A Study of Immune Cell Abnormalities Found in Individual Patients who have Type 1 Diabetes and are Waiting for Pancreas or Pancreas/Kidney Transplant Surgery

   Rochester, Minn.

   The purpose of this study is to measure and characterize specific immune cell abnormalities found in patients who have type 1 diabetes and may or may not be on the waiting list for either a pancreas alone or a pancreas and kidney transplant.

3. A Study to Evaluate the Effect of Inspiratory Muscle Training on Physiological Function and Clinical Outcomes Following Lung Transplant

   Jacksonville, Fla.

   The purpose of this study is to to mechanistically investigate the effect of specific inspiratory muscle training on respiratory function, exercise capacity, health-related quality-of-life, and short-term clinical outcomes in patients after lung transplant.

4. APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

   Rochester, Minn.

   The purpose of this study is to attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.

5. Vancomycin for Primary Sclerosing Cholangitis

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to to assess the effects of different Oral Vancomycin (OV) doses on the clinical and biochemical course in adult patients with Primary Sclerosing Cholangitis (PSC).

6. Lost Wages Support for Living Organ Donors Demonstration Project

   Scottsdale/Phoenix, Ariz.

   The purpose of this study will be to evaluate the effect of the US Health Resources and Services Administration (HRSA) program to reimburse lost wages on the decision of individuals to initiate evaluation for living organ donation.

7. TruGraf® Long-term Clinical Outcomes Study

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate post-transplant clinical outcomes in receipients of kidney transplants who are undergoing TruGraf® and TRAC™ monitoring.

    

8. A Study to Compare Medical and Non-Medical Coping on Functional Outcomes and Caregiver Burden Among Liver Transplant Patients

   Jacksonville, Fla.

   The purpose of this study is to compare functional improvement and caregiver burden pre- and post-liver transplant (LT) in four patient and patient’s primary caregiver dyads, grouped, based on presence or absence of mood symptoms pre-LT.

9. A Study of Kidney Transplant Recipients: Development of a Database for a Multicenter Consortium

   Rochester, Minn.

   The purpose of this study is to collect and share detailed clinical data from all kidney transplant recipients from 7 kidney transplant centers (Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Jacksonville, FL; Cornell University, New York, NY; University of Michigan, Ann Arbor, MI; Henry Ford, Detroit, MI; University of Pittsburgh Medical Center, Pittsburg, PA) to retrospectively and prospectively study kidney transplant recipients.

10. A Study to Evaluate the Effectiveness and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

    Rochester, Minn.

    The purpose of this study is to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have an active antibody mediated rejection (AMR) after recently been kidney transplanted. The purpose is also to investigate and compare safety for these two treatments. 20 patients will be treated with imlifidase and 10 with PE.